Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts. Thermo Fisher Scientific (TMO) Partners With AIM ImmunoTech on Phase 3 Cancer Trial On March 2, 2026, AIM ImmunoTech announced entering into an agreement with the PPD clinical research business of Thermo Fisher Scientific (TMO) to design a pivotal Phase 3 clinical trial for Ampligen. The study will evaluate the drug as a treatment for late-stage pancreatic cancer. It will utilize t ...

2026.03. 24 本文字数：2990，阅读时长大约5分钟 作者 | 第一财经 吴斯旻 "十五五"规划纲要明确提出实施健康优先发展战略，并将生物制药列为新兴支柱产业，为跨国医药企 业参与"健康中国"建设提供了新机遇。 近日，"中国发展高层论坛2026年年会"（下称"年会"）召开。年会期间，国家卫健委和中央财经委等 有关部门均释放了深化医药卫生体制改革、促进医疗等重点领域科技创新、优化营商环境和加大对外 开放的积极信号。 多名与会跨国医药企业高管均积极回应，将扩大在华业务，加大在细胞疗法等前沿领域的本地化生产 能力，继续投资本地创新并加强创新合作。 在深度参与中国医药创新的过程中，这些跨国医药企业对中国医药创新生态也有更多期待：其一，优 化完善与创新相匹配的知识产权保护体系、价值认定和支付机制，为企业提供制度性激励；其二，以 临床需求为导向，推动市场和监管的关注点从产品创新转向系统性集成创新，加大中国在疾病治理和 创新方案上的输出能力，完善涵盖患者、医疗机构、国内外制药企业和科研院所、社会资本以及监管 部门等多方的医药创新生态。 跨国药企深化在华布局 据国家卫健委消息，22日，上述年会"谋划'十五五'国民健 ...

Core Viewpoint - The share price of Thermo Fisher (TMO) has declined by approximately 20% since the beginning of 2026, presenting an attractive entry point for investors [1]. Company Analysis - The investment approach focuses on fundamental, bottom-up stock analysis, emphasizing the understanding of business models, competitive positioning, and long-term value creation through disciplined valuation work [1]. - The company seeks to identify firms with resilient cash flows, strong capital allocation, and durable competitive advantages, particularly in the technology, healthcare, and utilities sectors [1]. - There is a keen interest in how company fundamentals interact with broader macroeconomic developments, including monitoring key macro indicators such as interest rates, inflation, credit conditions, and policy developments [1]. Investment Strategy - The investment strategy includes stock picking and portfolio management within institutional investment environments, contributing to idea generation and portfolio construction [1]. - The objective is to provide clear, independent analysis with a long-term investment perspective, grounded in fundamental analysis and valuation discipline [1].

Emerald Wealth Partners, an independent asset and wealth management firm based in Zurich, released its Q4 2025 investor letter for the “Growth Equity Strategy.” A copy of the letter is available to download here. In 2025, the strategy returned +3.1% (gross) and +3.0% (net), resulting in the year-to-date return of 16.7% (gross) and +16.0% (net). Discussions on a potential bubble in Artificial Intelligence (AI) markets were a significant feature of 2025, especially in Q4, contributing to a pullback in AI sto ...

Core Insights - Thermo Fisher Scientific Inc. is recognized as one of Goldman Sachs' top healthcare stocks, with a strong strategic outlook presented by CEO Marc Casper at the 47th Annual Raymond James Institutional Investor Conference [1]. Group 1: Growth Prospects - The company is positioned to achieve a growth rate of 3% to 4% by 2026, building on a 2% organic growth from the previous year and targeting a long-term expansion rate of 5% to 6% [3]. - Growth will be driven by the integration of AI to enhance operations and capitalize on market opportunities, alongside a focus on mergers and acquisitions to strengthen the core business [3][4]. Group 2: Acquisition Strategy - Thermo Fisher is in the process of completing the acquisition of Olink, which is expected to enhance its endpoint solution capabilities [4]. - The company is also targeting additional acquisitions aimed at delivering high value to customers and generating strong returns [4]. Group 3: Market Position - Thermo Fisher Scientific is a global leader in serving science, providing over 2 million products and services across pharmaceutical development, biotechnology research, clinical diagnostics, and laboratory management [5].

Core Insights - The article emphasizes the importance of precise insights and efficient verification capabilities as key competitive advantages in the semiconductor industry, particularly as technology advances towards higher yield and reliability [2]. Event Details - The Thermo Fisher Semiconductor Solutions Seminar will take place on March 24, 2026, from 13:00 to 18:30 at the Thermo Fisher Customer Experience Center in Shanghai [3]. - The event will be conducted both online and offline, and registration is free [6]. Seminar Topics - The seminar will cover various topics including: - Physical and electrical failure analysis techniques - ESD testing and failure path verification - Multi-dimensional collaborative analysis methods - Semiconductor analysis solutions in the AI era [4]. Agenda Highlights - The agenda includes: - Welcome Speech by Trisha Rice - Introduction of Thermo Fisher's latest integrated spherical aberration-corrected TEM by Guittet Pierre-Yves - Presentation on next-generation focused ion beam systems by Michael Rauscher - Live demonstrations of Helios 5 Hydra, Helios 6 HD, and ELITE [7].

摘要： 海关总署2025年超高效液相色谱-三重四极杆质谱仪采购项目公布中标结果，赛默飞以2507万元独家中标23 台，型号为TSQ Quantis Plus。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 海关总署2025年超高效液相色谱-三重四极杆质谱仪（第三批）采购项目（重新招标）中标结 果已公布。在此次竞标中， 赛默飞独家中标 ，共计 斩获23台超高效 液相色谱-三重四极杆质谱仪大单，中标金额合计2507万元。 为了符合国家要求，供应商提供了中标产品 "符合本国产品标准"声明函 ： 具体中标详情如下： 一、项目编号：CG2025-PL-GK-HW-096-C01 二、项目名称：海关总署2025年超高效液相色谱-三重四极杆质谱仪（第三批）采购项目（重 新招标） 三、中标信息 供应商名称：广州市东方科苑进出口有限公司 供应商地址：广州市越秀区先烈中路100号大院8号楼三楼（自编306）（仅限办公用途） 中标金额：25,070,000.00元 评审总得分：98.143分 四、主要标的信息： | 供应商 | 货物 | 货物 | 货物 | 货 ...

Core Viewpoint - The article emphasizes the importance of maintaining laboratory instruments in optimal condition to meet the demands of high-intensity testing tasks in the new year, highlighting the services provided during the sixth Customer Care Season by the Instrument Information Network [1]. Group 1: Event Overview - The theme for this year's event is "'Together in Instruments," featuring hundreds of engineers and a week-long online after-sales live broadcast to support researchers in their scientific endeavors [2]. - The event includes free on-site inspections valued at over 10,000 yuan, with original factory experts addressing potential issues directly [2]. Group 2: Participating Brands - The event features participation from various brands including Thermo Fisher, Agilent, Hitachi, Shimadzu, and others, providing specialized support for different types of analytical instruments [2]. Group 3: Event Schedule - The schedule includes specific sessions for different brands, such as: - March 10: Thermo Fisher after-sales live broadcast focusing on maintenance tips for mass spectrometry and gas chromatography [4]. - March 11: Shimadzu's session on atomic absorption maintenance and gas chromatography performance [5]. - March 12: Hitachi's session on electron microscope maintenance and amino acid analyzer guidelines [5]. Group 4: Expert Contributions - Various experts from participating companies will lead the sessions, sharing their knowledge on maintenance and troubleshooting for specific instruments, enhancing the overall service quality [7][8].

Core Insights - Thermo Fisher Scientific Inc. (NYSE:TMO) is recognized as a consistently growing stock in the market [1] Group 1: New Developments - The company announced the opening of its Cryo-Electron Microscopy (cryo-EM) Drug Discovery Center in South San Francisco, aimed at providing biotechnology and pharmaceutical innovators with advanced cryo-EM technologies [2] - The new center facilitates direct access to cryo-EM innovation and scientific expertise, significantly lowering barriers to adoption for pharmaceutical companies [3] Group 2: Benefits of Cryo-EM - Cryo-EM technology is expected to expand the range of therapeutic targets and advanced therapies, enabling faster drug development for pharmaceutical companies [3] - Structure-guided drugs developed using cryo-EM have over twice the rate of clinical success, with half the preclinical time and cost compared to industry standards [3] Group 3: Company Overview - Thermo Fisher Scientific Inc. provides a wide range of analytical instruments, reagents, equipment, software, and services for analysis, research, diagnostics, and discovery, operating through various segments including Analytical Instruments, Life Sciences Solutions, Laboratory Products and Services, and Specialty Diagnostics [5]

Core Insights - Generative AI is viewed as a transformative technology by Amazon's CEO Andy Jassy, indicating its potential to significantly enhance customer experiences across the company [1] - Elon Musk predicts that by 2040, humanoid robots could create a market worth $250 trillion, representing a major shift in the global economy driven by AI innovation [2][3] - Major firms like PwC and McKinsey acknowledge the potential of AI to unlock multi-trillion-dollar opportunities, reinforcing the optimistic outlook on AI's economic impact [3] Company and Industry Analysis - A breakthrough in AI technology is believed to be redefining work, learning, and creativity, leading to increased interest from hedge funds and top investors [4] - There is speculation about an under-owned company that may play a crucial role in the AI revolution, suggesting that it could be a significant investment opportunity [4][6] - Prominent figures in technology and finance, including Bill Gates and Warren Buffett, recognize AI as a major technological advancement with the potential for substantial social benefits [8]